E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed 28 enrolled Eisai Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with carboplatin and paclitaxel to patients with advanced or metastatic non-small cell lung cancer.

Timeline

Start: 2009-02
Primary completion: 2011-07
Completion: 2011-10

Publications

Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer. 2013 Aug 6;109(3):538-44. doi: 10.1038/bjc.2013.374. Epub 2013 Jul 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenvatinib	Small molecule	4 mg	Oral
Subject	Lenvatinib	Small molecule	6 mg	Oral
Background	Carboplatin	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	200 mg/m2	Intravenous

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Summary

Timeline

Publications

Drugs

Indications